TABLE 4.
n (%) | ||
---|---|---|
Reference Trastuzumab (N=27) | Biosimilar Trastuzumab (N=12) | |
No decrease | 7 (25.9) | 4 (33.3) |
Decrease of <10 points from baseline | 14 (51.9) | 6 (50.0) |
Decrease of ≥10 points from baseline | 6 (22.2) | 2 (16.7) |
<50 points and decrease of ≥10 points from baseline | 1 (3.7) | 1 (8.3) |